← All trials
NCT05639153
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 13, 2022
- Primary completion
- Sep 30, 2023
- Completion date
- Apr 30, 2024
- First posted
- Dec 6, 2022
- Last posted
- Dec 6, 2022
- Enrollment
- 94
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Zhejiang Doer Biologics Co., Ltd.Lead sponsor
- Zhejiang UniversityOverall official - principal investigator
- Zhejiang Doer Biologics Co., Ltd.Study chair
- Huadong Medicine Co., Ltd.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.